| Paper | Title | Page |
|---|---|---|
WEBO02 |
Cyclotron-Based Medical Radionuclides and Their Applications in Radiopharmaceuticals | |
|
||
| Liu group is centered on developing radiopharmaceuticals and radiochemical tools for probing and perturbing biological processes in living systems, with a particular focus on cancer. We have developed a series of medical radionuclides with self-developed equipment and purification processes, including Y-86, Zr-89, In-111, Ac-225 , Bi-212, Bi-213, Pb-212 and etc. Our research mainly follows three lines of efforts: 1) Novel in vivo chemistry that enables PET imaging probes for localized protein activation and controlled drug release (Nature 2020; ACS Cent Sci 2022; J Am Chem Soc 2021; Angew Chem 2021); 2) Radiotherapy-activated prodrugs (JACS, 2022; Angew Chem 2022; Angew Chem 2020); 3) Cyclotron production of medical radionuclides, development and translational study of new radiopharmaceuticals for cancer theranostics (Nat Comm 2022; Nat Com 2022; JNM 2022; EJNMMI 2022). | ||
| Cite • | reference for this paper using ※ BibTeX, ※ LaTeX, ※ Text/Word, ※ RIS, ※ EndNote (xml) | |